Affordable Access

deepdyve-link
Publisher Website

Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

Authors
  • Detoc, Maëlle1
  • Bruel, Sébastien1, 2, 3
  • Frappe, Paul1, 2, 3
  • Tardy, Bernard1
  • Botelho-Nevers, Elisabeth1, 4, 3
  • Gagneux-Brunon, Amandine1, 4, 3
  • 1 Centre d’investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France
  • 2 Department of General Practice, Faculté de Médecine Jacques Lisfranc, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
  • 3 PRESAGE Insitute, Université de Lyon, Saint-Etienne, France
  • 4 Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
Type
Published Article
Journal
Vaccine
Publisher
Elsevier Ltd.
Publication Date
Sep 17, 2020
Volume
38
Issue
45
Pages
7002–7006
Identifiers
DOI: 10.1016/j.vaccine.2020.09.041
PMID: 32988688
PMCID: PMC7498238
Source
PubMed Central
Keywords
License
Unknown

Abstract

Introduction The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial. Methods We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial. Results Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2–79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9–49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial. Conclusions Nearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.

Report this publication

Statistics

Seen <100 times